This article outlines clinical guidelines for treating acetaminophen toxicity, emphasising the importance of patient history and acetylcysteine administration. It also highlights the evolving landscape of acetaminophen poisoning and the need for further research in this field.

---

What is the proper way to treat acetaminophen toxicity from a single or repeated intake?

The objective of this qualitative research was to give specific clinical guidelines on the evaluation, management, and treatment of acetaminophen intoxication. It did this by using an expert-derived consensus in accordance with a modified Delphi approach.

Purpose: These suggestions justify present methods of treating acetaminophen intoxication.

Inadvertent overconsumption of repeated dosages of acetaminophen (paracetamol) while treating pain or fever may also result in acetaminophen toxicity. Acetaminophen's toxic effects are illustrated by hepatocellular destruction, which may result in acute liver injury, acute liver failure, or even death.

It's necessary to have clinical guidelines for treating acetaminophen intoxication. Acetaminophen poisoning has changed significantly over the last 25 years due to many factors including the development of medicines with higher acetaminophen concentrations, extended-release formulations, and novel combination medications that combine acetaminophen with opioids or other substances.

The reasons for variations in treatment seem to be related to:

• Patient behaviour
• Other medical specialisations
• Staffing levels in emergency departments (EDs)
• Poison centres (PCs)
• Differences in the availability of resources

Recommendations for treating individuals with acetaminophen intoxication are provided in a consensus statement that has recently been published in JAMA. A total of 84 recommendations and 278 scholarly articles were reviewed.

The group created recommendations for treating acetaminophen consumption, whether it occurs once or often, in emergency departments.

The panel also discussed:

• The use of extended-release formulations
• High-risk consumption
• The co-administration of opioids and anticholinergics
• Age under 6 years, pregnancy
• Weight above 100 kg
• Intravenous acetaminophen usage

To maximise the treatment of patients with acetaminophen poisoning, this qualitative research offers a consensus statement on consistent evidence-based guidelines for medical, pharmacy, and nursing education and practice.

---

How to deal with an acute ingestion of potentially immediate-release acetaminophen

The most typical event associated with acetaminophen toxicity is acute consumption. The importance of the patient's history was stressed by the panel.

Despite its significance, very few papers assess how to get a reliable history. The committee classified a history as unreliable or incorrect if it did not provide enough information to determine the dosage and timing of intake, if it included contradictory information, or if the patient's symptoms, signs, or laboratory results did not match the history.

When in question, the history needs to be regarded as untrustworthy, and the procedures for dealing with unknown or untrustworthy history ought to be adhered to.

The panel decided to include only lines that direct therapeutic action in their revision of the Rumack-Matthew nomogram. Acetylcysteine is given to individuals whose blood acetaminophen concentration is over the treatment line, and the blood concentration is simply plotted on the nomogram.

Revised Rumack-Matthew nomogram for the acute ingestion of acetaminophen

---

Acetylcysteine therapy

1. Both oral and intravenous forms of acetylcysteine are available for use.
2. The first dosage needs to be given as soon as it is clear that therapy is required.
3. More than 15 distinct regimens were found, however, the comparative efficacy of these regimens has not been assessed.
4. During the first 20 to 24 hours of therapy, the panel advised using a regimen that provides at least 300 mg/kg orally or intravenously.
5. The guideline specifies the criteria for ceasing the administration of acetylcysteine.
6. A typical mistake made by clinicians is to start giving acetylcysteine and stop it without reevaluating the patient after 20 or 21 hours. Some patients, meanwhile, need more time spent receiving care. It is advised to keep giving acetylcysteine until the stopping requirements are satisfied.

---

Ingestion of large amounts of acetaminophen

1. Ingestion of at least 30 g of acetaminophen or a concentration of acetaminophen above the high-risk line on the nomogram is considered a high-risk ingestion.
2. The management of high-risk ingestions is the same as that of other acetaminophen products, with the caveat that because of prolonged absorption, the administration of activated charcoal may be warranted more than 4 hours after ingestion.
3. If the patient exhibits signs of mitochondrial dysfunction, such as altered consciousness, metabolic acidosis, or hyperlactatemia, additional laboratory testing is indicated.
4. The evaluation should also include an assessment of other possible causes of altered consciousness. Lastly, an increased dosage of acetylcysteine may be necessary after consulting with a clinical toxicologist.

---

Managing excessive dose consumption

As opposed to a patient with an acute ingestion, management for repeated supratherapeutic ingestion is based on the patient's presentation.

If the acetaminophen concentration is higher than 20 μg/mL (multiply by 6.614 to convert to micromoles per litre) or if the level of aspartate or alanine aminotransferase is abnormal, acetylcysteine should be given until the stopping criteria are met.

---

Consuming products with extended-release acetaminophen

1. Acetaminophen products labelled for 8 hours of use that are available are referred to as extended-release.
2. Management is the same as for consumption of other acetaminophen products except that activated charcoal may be beneficial more than 4 hours after ingestion if signs of continued absorption are observed (i.e., an increased acetaminophen concentration).
3. Acetylcysteine is required if samples taken 4 to 24 hours after ingestion show an acetaminophen concentration above the nomogram treatment line.
4. If the concentration from samples obtained 4 to 12 hours after consumption is below the treatment line but over 10 μg/mL, it should be tested again 4 to 6 hours after the first measurement.

---

Combining acetaminophen with drugs that are anticholinergic or opioid antagonists

The clinical issue is that acetaminophen absorption may be extended or delayed when used with anticholinergic or opioid agonist medicines.

The management of this medication is the same as that of other acetaminophen products, with the exception that acetylcysteine therapy is not required if the initial acetaminophen concentration, tested 4 to 24 hours after intake, is 10 μg/mL or less. Acetylcysteine is required if the concentration is higher than the treatment line in any way.

A second measurement should be done 4 to 6 hours after the first measurement if the patient exhibits anticholinergic or opioid clinical symptoms and the acetaminophen concentration recorded 4 to 24 hours after intake is more than 10 μg/mL but less than the treatment line on the updated nomogram. The same as with other acetaminophen ingestions, the dosage and length of acetylcysteine treatment.

---

Using improved elimination methods

When there has been a very big consumption, enhanced elimination is advised. The consensus panel agreed that poisoning should be treated extracorporeally.

For patients who have an acetaminophen concentration of 900 μg/mL or more and have acidosis or altered consciousness as a result of the toxic effects of acetaminophen, hemodialysis is advised in addition to acetylcysteine therapy.

Acetylcysteine infusion rates during hemodialysis should be at least 12.5 mg/kg per hour if the intravenous route is used. There is no need to modify the oral acetylcysteine regimen when receiving hemodialysis.

Treatment of acetaminophen poisoning is essential for optimal patient outcomes and cost-effective care.

Missed diagnoses, postponed therapy, or interrupted acetylcysteine infusions might result from failure to recognise the significance of the patient history and from making mistakes in patient care.

A policy that offers managerial direction may improve patient outcomes, lessen disturbances for both patients and caregivers and shorten hospital stays.

Several changes have been made to the way acetaminophen poisoning is managed, these include:

1. The introduction of extended-release acetaminophen formulations.
2. The importance of the patient's history.
3. The a lack of high-quality evidence to support the selection of a particular acetylcysteine regimen.
4. The early termination of acetylcysteine infusion.
5. The introduction of acetaminophen for intravenous administration in 2011.

Although it has been suggested that fomepizole be added to acetylcysteine to treat significant acetaminophen ingestions, the available evidence did not support a routine prescription. Any severe or complex acetaminophen intoxication should be evaluated by a clinical toxicologist.

---

Disclaimer- The views and opinions expressed in this article are those of the author and do not necessarily reflect the official policy or position of M3 India.

About the author of this article: Dr Monish Raut is a practising super specialist from New Delhi.